@article{Hu2025, 
author = {Xiao Hu and Fei Li and Xin-Hang Qian and Yu-Sen Zhang and Shuai Ke and Yun-Xia Jin and Shuai Yuan and Yuan-Yuan Zhang and Rui Li and Lei Cao and Lang Rao and Xian-Tao Zeng and Ling-Ling Zhang},
title = {Mild photothermal therapy-enhanced nano-ferroptosis inducer for potent treatment of advanced prostate cancer},
year = {2025},
journal = {Nano Research},
volume = {18},
number = {4},
pages = {94907314},
keywords = {chemodynamic therapy, prostate cancer, ferroptosis, mesoporous polydopamine, mild photothermal therapy},
url = {https://www.sciopen.com/article/10.26599/NR.2025.94907314},
doi = {10.26599/NR.2025.94907314},
abstract = {Androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSis) often have limited efficacy in patients with advanced prostate cancer (PCa) (especially AR-negative). Inducing ferroptosis in PCa cells is an attractive therapeutic approach. In this work, mesoporous polydopamine nanoparticles (MPDA NPs) were developed to simultaneously deliver Cu+/Cu2+ ion pairs and glutathione peroxidase 4 (GPX4) inhibitor RSL3 to tumor sites for enhanced treatment of PCa. The prepared MPDA-Cu-RSL3@HA (MPCRH) NPs induced ferroptosis by promoting lipid peroxidation and regulating phospholipid profiles in PCa cells, and the above effects were further enhanced by mild photothermal therapy (mPTT) without damaging normal tissues. mPTT can promote reactive oxygen species (ROS) generation and degrade tumor extracellular matrix in vivo to promote nanodrugs intratumoral penetration. In short, this work shows the great application potential of mPTT-enhanced nano-ferroptosis inducers in the field of PCa treatment, in order to provide a reasonable paradigm for nanodrug development and PCa treatment.}
}